A106 USTEKINUMAB IS EFFECTIVE FOR MAINTAINING CLINICAL RESPONSE IN REFRACTORY MODERATE-TO-SEVERE CROHN’S DISEASE: A MULTICENTRE COHORT STUDY

BACKGROUND: Ustekinumab is a monoclonal antibody targeting interleukins 12 and 23. Ustekinumab has recently been approved for treatment of Crohn’s disease by the United States Food and Drug Administration but long-term maintenance of clinical response in the real-world setting is unclear. AIMS: To a...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:J Can Assoc Gastroenterol
Egile Nagusiak: Ma, C, Fedorak, R, Kaplan, G G, Dieleman, L A, Devlin, S, Stern, N, Kroeker, K I, Seow, C, Leung, Y, Novak, K L, Halloran, B P, Huang, V, Wong, K, Ghosh, S, Panaccione, R
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Oxford University Press 2018
Gaiak:
Poster Presentations
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6507754/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jcag/gwy008.107
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak